Skip to main content
UCBJY logo

UCB S.A. (UCBJY) Stock Price & Analysis

UCB S.A. (UCBJY) — price $154.96 (-0.66%), as of the Nov 19, 2026 trading session; market cap $59.0B. Expected results Feb 25, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$154.96 −$1.03 (-0.66%) Market Cap $59.0B

UCB S.A. · UCBJY · Healthcare · Biotechnology

UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RPRX · Royalty Pharma plc · 73 /100
  • REGN · Regeneron Pharmaceuticals, Inc. · 95 /100
  • GMAB · Genmab A/S · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$154.96
Change on the day-0.66%
52-week range$110.55–$168.76
Market capitalisation$59.0B—
Price / earnings (trailing)24.83
Shares traded on the day2.6K
Beta (volatility vs the S&P 500)0.2

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $114, high $165, latest $155. 2 reported quarters marked, 2 above and 0 below the recorded estimate. $165 $114 high $165 Feb 26, 2026 · Earnings results · reported above the recorded estimate · close $1491Jul 30, 2026 · Earnings results · reported above the recorded estimate · close $1292 Oct 17, 2025 Nov 19, 2026 · $155 $146Oct 17, 2025$129Oct 31, 2025$132Nov 14, 2025$139Nov 28, 2025$138Dec 12, 2025$139Dec 26, 2025$148Jan 9, 2026$152Jan 23, 2026$155Feb 6, 2026$163Feb 20, 2026$146Mar 6, 2026$142Mar 20, 2026$153Apr 2, 2026$153Apr 17, 2026$135May 1, 2026$137May 15, 2026$146May 29, 2026$159Jun 12, 2026$147Jun 26, 2026$136Jul 10, 2026$139Jul 24, 2026$129Aug 7, 2026$129Aug 21, 2026$122Sep 4, 2026$120Sep 18, 2026$115Oct 2, 2026$114Oct 16, 2026$156Oct 30, 2026$164Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for UCB (UCBJY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Strong
Revenue Growth Strong
Debt/Equity Neutral
ROE Strong
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is UCB (UCBJY), and what does it report?

Short answer

UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. UCB S.A. (UCBJY) is classified as Healthcare / Biotechnology. Headquarters: Allée de la Recherche, 60, Brussels, BU, 1070, BE. It employs 10,117 people and is led by Jean-Christophe Tellier. In Q2 FY2026 it reported revenue of €4.35B and net income of €1.13B. The market values it at $59.0B.

2 · Latest results

What do the latest results show for UCB (UCBJY)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of €4.35B. Against analyst estimates the company has EPS beat 8 of the last 8 reports.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$4.91B Jul 30, 2026
Latest report · revenue estimate
$4.64B Jul 30, 2026
Latest report · revenue vs estimate
Above estimate Jul 30, 2026
Latest report · EPS vs estimate
Above estimate Jul 30, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Jul 30, 2026$4.91B$4.64B$3.9300$2.9100
Feb 26, 2026$5.02B$4.96B$3.7900$2.9100
Jul 31, 2025$3.99B$3.74B$2.0200$1.9300
Feb 27, 2025$3.56B$3.20B$1.5500$1.3500
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026€4.35B€1.13B€2.92 (diluted)
Q4 FY2025€4.22B€1.07B€2.77 (diluted)
Q2 FY2025€3.49B€475M€1.22 (diluted)
Q4 FY2024€3.36B€857M€2.21 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for UCB (UCBJY)?

Short answer · as of

The distress and quality screens read Altman Z 5.19 · Piotroski F 6. Trailing ratios: ROE 20.6% · ROA 8.3% · current ratio 1.20.

4 · What to check next?

What should you watch next at UCB (UCBJY)?

Short answer · as of

The next earnings report is expected on Feb 25, 2027.

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • No forward revenue or earnings estimate is on file.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held UCBJY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported UCBJY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about UCB (UCBJY)?

Read these with our analysis →

UCB Healthcare Stock: Key Questions Answered

Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.

What does BIMZELX add to UCB’s immunology franchise?

BIMZELX extends UCB’s immunology reach across several inflammatory conditions already adjacent to Cimzia’s markets. Its contribution matters not only for sales growth but also for the product mix management expects to offset pricing pressure.

How do Nayzilam and UCB’s epilepsy medicines fit together?

Briviact, Vimpat and Keppra serve epilepsy management, while Nayzilam addresses seizure clusters through an emergency nasal spray. That gives UCB exposure to ongoing neurological treatment as well as acute intervention within the same franchise.

What is the UCBJY stock price today?

The last price recorded for UCB S.A. (UCBJY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 39 figures on this page — 33 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • FAQ: What does BIMZELX add to UCB’s immunology franchise?: Business description; Management outlook — dated call excerpts
  • FAQ: How do Nayzilam and UCB’s epilepsy medicines fit together?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.